# Neurobiological mechanisms of prescription opioid withdrawal

> **NIH NIH R01** · MCLEAN HOSPITAL · 2020 · $361,563

## Abstract

Project Summary
This R01 proposal was written in response to PA-16-233 “Prescription Drug Abuse”. Prescription opioid abuse
is a major public health concern for both men and women. Although opioid addiction has historically exhibited a
substantially higher prevalence in men, the gender gap is closing, underscoring the need to conduct research
in both sexes. The opioid withdrawal syndrome, characterized by an acute physical syndrome and a long-
lasting affective syndrome that includes anhedonia, anxiety, and drug cravings, is a major factor in escalation
of opioid use and relapse. Cumulative work from our laboratory and others suggests that opioid withdrawal
increases glutamate-mediated activation of the nucleus accumbens shell (NASh), which contributes to the
withdrawal syndrome. For example, we have shown that morphine dependence is associated with increased
neuronal surface expression of the AMPA glutamate receptor (AMPAR) GluA1 subunit in the NASh, and
withdrawal-induced depressive-like states require NASh GluA1 AMPAR activation. It has also been shown that
activation of glutamatergic projections from the paraventricular nucleus of the thalamus (PVT) to the NASh is
required for expression of morphine withdrawal signs. However, this prior research has been conducted
primarily in male rodents that experience withdrawal after experimenter-administered opioids. The regulation
and role of NASh glutamatergic signaling in withdrawal from self-administered opioids in males and females is
not known. The objective of this proposal is to build on these findings and examine how projection-specific
(PVT to NASh) AMPAR-mediated signaling contributes to negative affective states triggered by withdrawal
from oxycodone self-administration (SA) in male and female rats. Our central hypothesis is that oxycodone SA
triggers projection-specific increases in AMPAR-mediated signaling in the NASh necessary for expression of
negative affective states and relapse. We will address this hypothesis in 4 aims in which male and female rats
will be exposed to long-access (LgA) oxycodone SA for 2 weeks followed by 2 weeks of abstinence. In Aims 1
and 2 we will examine how withdrawal from LgA oxycodone affects extracellular glutamate levels and synaptic
transmission in the NASh using microdialysis (Aim 1) and slice electrophysiology paired with optogenetic
activation of PVT to NASh projections (Aim 2). In Aims 3 and 4 we will determine if glutamate release and
activation of AMPARs in the NASh is necessary for oxycodone withdrawal-induced negative affective states,
as measured with intracranial self-stimulation. We will use chemogenetic modulation of PVT to NASh
projections to regulate glutamate release (Aim 3) and viral vector-mediated expression of GluA1ct, which has
been shown to block activity-dependent trafficking of GluA1 subunits, to regulate AMPAR transmission in the
NASh (Aim 4). Data from these studies will establish a mechanistic link between projection-specific
gluta...

## Key facts

- **NIH application ID:** 9957083
- **Project number:** 5R01DA045000-04
- **Recipient organization:** MCLEAN HOSPITAL
- **Principal Investigator:** ELENA H CHARTOFF
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $361,563
- **Award type:** 5
- **Project period:** 2017-09-15 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9957083

## Citation

> US National Institutes of Health, RePORTER application 9957083, Neurobiological mechanisms of prescription opioid withdrawal (5R01DA045000-04). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9957083. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*